RJA
CVS icon

Raymond James & Associates’s CVS Health CVS Stock Holding History

Raymond James & Associates’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,900
Closed -$1.18M – 3864
2023
Q1 		$1.18M Sell
16,900
-14,100
-45% -$1.18M ﹤0.01% 2357
2022
Q4 		$4.34K Buy
31,000
+1,600
+5% +$154K ﹤0.01% 3884
2022
Q3 		$12K Buy
29,400
+600
+2% +$59.4K ﹤0.01% 3843
2022
Q2 		$5K Sell
28,800
-3,300
-10% -$322K ﹤0.01% 3971
2022
Q1 		$8K Buy
32,100
+2,900
+10% +$305K ﹤0.01% 4071
2021
Q4 		$77K Sell
29,200
-43,100
-60% -$3.98M ﹤0.01% 3902
2021
Q3 		$912K Sell
72,300
-1,000
-1% -$83.8K ﹤0.01% 2645
2021
Q2 		$886K Sell
73,300
-23,700
-24% -$1.94M ﹤0.01% 2674
2021
Q1 		$563K Sell
97,000
-24,900
-20% -$1.81M ﹤0.01% 2933
2020
Q4 		$266K Buy
121,900
+26,800
+28% +$1.74M ﹤0.01% 3197
2020
Q3 		$27K Sell
95,100
-45,400
-32% -$2.82M ﹤0.01% 3494
2020
Q2 		$188K Buy
140,500
+3,600
+3% +$227K ﹤0.01% 3150
2020
Q1 		$131K Sell
136,900
-11,700
-8% -$781K ﹤0.01% 3156
2019
Q4 		$862K Buy
148,600
+32,500
+28% +$2.28M ﹤0.01% 2362
2019
Q3 		$154K Buy
116,100
+45,500
+64% +$2.7M ﹤0.01% 3332
2019
Q2 		$45K Buy
70,600
+2,600
+4% +$140K ﹤0.01% 3510
2019
Q1 		$71K Sell
68,000
-2,500
-4% -$154K ﹤0.01% 3441
2018
Q4 		$278K Sell
70,500
-26,200
-27% -$1.96M ﹤0.01% 2917
2018
Q3 		$821K Sell
96,700
-8,100
-8% -$579K ﹤0.01% 2381
2018
Q2 		$316K Buy
104,800
+31,300
+43% +$2.06M ﹤0.01% 2985
2018
Q1 		$176K Buy
73,500
+56,900
+343% +$4.08M ﹤0.01% 3171
2017
Q4 		$1K Sell
16,600
-1,900
-10% -$138K ﹤0.01% 3411
2017
Q3 		$4K Buy
18,500
+800
+5% +$63.3K ﹤0.01% 3377
2017
Q2 		$17K Buy
17,700
+6,100
+53% +$482K ﹤0.01% 3267
2017
Q1 		$1K Sell
11,600
-2,600
-18% -$208K ﹤0.01% 3284
2016
Q4 		$33K Buy
+14,200
New +$1.15M ﹤0.01% 3121

Other funds holding CVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Raymond James & Associates's CVS Position: Q3 2024 in Review

Raymond James & Associates reduced its CVS Health (CVS) stake by 11% in Q3 2024, selling an estimated $14.3M and leaving 2,041,004 shares worth $128M. The position accounts for 0.08% of the portfolio, ranked #213.

Raymond James & Associates first reported a position in CVS in Q2 2013 and has held it in 46 quarters since. The position peaked at $353M in Q4 2021. 1,841 funds tracked by Wall St. Rank hold CVS as of Q3 2024.

  • Raymond James & Associates held 2,041,004 shares of CVS Health worth $128M as of Q3 2024.
  • Raymond James & Associates sold 245,468 CVS Health shares in Q3 2024, an estimated $14.3M.
  • CVS Health made up 0.08% of Raymond James & Associates's portfolio in Q3 2024, its #213 holding.
  • Raymond James & Associates first reported a position in CVS Health in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's CVS Health position peaked at $353M in Q4 2021.
  • 1,841 funds tracked by Wall St. Rank held CVS Health as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.